Natera, Inc. vs Pfizer, Inc. — Stock Comparison
Q·Score Breakdown
6
Neutral
Overall
6.5
Neutral
Quality
Health
Growth
Valuation
Sentiment
NTRA
Clean balance sheet with low leverage (0.1× debt-to-equity).
⚠ currently unprofitable (-9% margin).
PFE
Strong profitability with 12% net profit margins.
⚠ analyst sentiment is cautious.
Analyst Consensus
BUY
Target $258.00 (+24.5%)
18 analysts
HOLD
Target $29.00 (+10.2%)
27 analysts
Fundamentals
NTRA
PFE
—
Trailing P/E
19.4×
-305.6×
Forward P/E
9.4×
-9.0%
Profit Margin
12.4%
64.7%
Gross Margin
75.8%
-14.3%
ROE
8.9%
39.8%
Revenue Growth
-1.2%
—
Earnings Growth
—
1.68
Beta
0.39
—
Price / Book
—
$29.6B
Market Cap
$149.8B
$132 – $256
52-Week Range
$22 – $29
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →